What is Anoro Ellipta?
Anoro Ellipta is an inhaler that contains 2 different active ingredients that work together to help improve COPD symptoms.
COPD is a chronic lung condition that’s typically caused by damage to the lungs. This can cause inflammation in your airways, which can make breathing more difficult. Anoro Ellipta helps to open up your airways, to ease COPD symptoms.
How does Anoro Ellipta work?
Anoro Ellipta works in a couple of different ways to help keep your COPD symptoms in check.
It stops the muscles around your airways from tightening, as well as opening up the airways in your lungs.[1] This lets air pass through more easily, which should improve your lung function and relieve COPD symptoms.
What are Anoro Ellipta’s active ingredients?
Anoro Ellipta contains two active ingredients to help manage COPD.
The first active ingredient, umeclidinium, is a type of medicine called a long-acting muscarinic antagonist (or LAMA). It blocks a neurotransmitter that’s responsible for constricting the muscles around your airways. This helps to keep your airways open, and make it easier to breathe.[2]
The second is vilanterol, a long-acting beta-2 agonist (or LABA). It works by opening up the airways in your lungs, so air can pass in and out more easily.[3]
They’re known as long-acting drugs because they work for 24 hours after use.
How do Anoro Ellipta doses work?
Anoro Ellipta comes in a couple of different doses: a lower dose that contains 55 mcg of umeclidinium and 22 mcg of vilanterol, and a higher dose that contains 62.5 mcg umeclidinium and 25 mcg of vilanterol. At the moment, only the 62.5 mcg/25 mcg dose is available in the US.
Treated trusted source:
- CADT. (2017). Umeclidinium Bromide/Vilanterol Trifenatate (Anoro Ellipta). Canadian Agency for Drugs and Technologies in Health.
- Rowden, A. Aleskerov, F. (2022). What are LAMA, and how do they treat COPD? Medical News Today. 11 March.
- Rossi, A. Khirani, S. Cazzola, M. (2008). Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. International Journal of Chronic Obstructive Pulmonary Disease. 3(4). pp. 521-529.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.